Work

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

Year: 2012

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e31823c5b11

Authors: Andrew Weickhardt, Robert Doebele, Ana Oton, Janice Lettieri, DeLee Maxson, Michele Reynolds, Amy Brown, Mary K. Jackson, Grace Dy, Araba Adjei, Gerald Fetterly, Xian Lu, Wilbur Franklin, Marileila Varella-Garcia, Fred R. Hirsch, Murry W. Wynes, Hagop Youssoufian, Alex Adjei, D. Ross Camidge

Institutions: University of Colorado Cancer Center, Roswell Park Comprehensive Cancer Center, Colorado School of Public Health

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, U.S. Public Health Service, National Cancer Institute

Awards: G6098401007, SPORE in Lung Cancer

OpenAlex ID: W2145899075

FWCI: 8.497

Cites: 30

Cited by: 49

Related to: 10